ImmunoCellular Therapeutics, Operating Income

ImmunoCellular Therapeutics, (IMUC) currently reports a operating income of $-730K as of September 2023. That compares with $-2.2M in the prior-year period — up 65.9% year over year. Use the charts on this page to explore ImmunoCellular Therapeutics,'s operating income history and peer comparisons.

ImmunoCellular Therapeutics,'s operating income increased from $-2.2M to $-730K — a 65.9% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoCellular Therapeutics, reported $-730K in operating income as of September 2023. That compares with $-2.2M in the prior-year period — up 65.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-730K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunoCellular Therapeutics,, and consider following IMUC for alerts when major investors trade the stock.

ImmunoCellular Therapeutics, is classified in the Healthcare sector. On operating income, it currently shows $-730K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMUC with unrelated industries.